A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
NCT ID: NCT03781934
Last Updated: 2025-07-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
53 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-09-05
Study Completion Date
2025-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
NCT01108705
Carcinoma, Hepatocellular
TERMINATED
PHASE3
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
NCT05897138
Hepatocellular Carcinoma
NOT_YET_RECRUITING
PHASE2
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
NCT04044651
Hepatocellular Carcinoma
WITHDRAWN
PHASE2/PHASE3
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
NCT04211168
Advanced Biliary Tract Cancer
UNKNOWN
PHASE2
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT00105443
Carcinoma, Hepatocellular
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will be conducted in three phases. The initial phase, 1a, will enroll up to 12 subjects and include a total of one dose escalation per patient. Once pre-defined criteria for starting phase 1b monotherapy has been met among the enrolled patients in phase 1a, the next phase of the study will be initiated. Phase 1b monotherapy will enroll up to 30 patients in a 3+3 design with interpatient dose escalations. All dose escalation decisions will be made by a safety review committee that will meet regularly during the study conduct. When the MTD has been established, the SRC will provide a RP2D for monotherapy. Phase 1b combination constitutes an interpatient dose escalation to identify the RP2D for MIV-818 when used in combination with 1) lenvatinib and 2) pembrolizumab therapy. This part of the study will enroll up to 36 patients in a 3+3 design with interpatient dose escalations. Safety review will be performed by the SRC to determine the RP2D of MIV 818 for use in combination with lenvatinib and pembrolizumab. The SRC may recommend that the selected dose of MIV-818 is further evaluated in up to 30 patients in the Phase 2a expansion part of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatocellular Carcinoma
Intrahepatic Cholangiocarcinoma
Liver Metastases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Intrapatient dose escalations continuing into interpatient dose escalations to end with dose expansion cohorts.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Phase 2a expansion cohort HCC
Group Type
EXPERIMENTAL
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Intervention Type
DRUG
MIV-818 - oral capsules; pembrolizumab - IV
MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Phase 2a expansion cohort HCC
Group Type
EXPERIMENTAL
MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Intervention Type
DRUG
MIV-818 - oral capsules; lenvatinib - oral capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
MIV-818 - oral capsules; pembrolizumab - IV
Intervention Type
DRUG
MIV-818 (fostroxacitabine bralpamide) + lenvatinib
MIV-818 - oral capsules; lenvatinib - oral capsules
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female ≥ 18 years of age on the day of signing informed consent.
2. Able to understand and voluntarily sign a written informed consent and is willing, and able, to comply with the protocol requirements.
3. Must have measurable disease based on RECIST v1.1 as determined by the site study team. Must have at least 1 target lesion in the liver. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
4. Must have a Child-Pugh A status for Phase 1a and a Child-Pugh A or B status for Phase 1b and 2a. SRC discretion to restrict to Child-Pugh A status for Phase 1b and 2a.
5. Must have an ECOG performance status of 0 or 1 at Screening.
6. Must have life expectancy of \> 12 weeks in the investigator's opinion.
7. Must have ALT and AST ≤ 5.0 × upper limit of normal (ULN) at Screening.
8. Must have total bilirubin (TBil) ≤ 3.0 mg/dL at Screening.
9. Must have adequate renal function with estimated creatinine clearance
≥ 60 mL/min (based on Cockcroft and Gault formula or similar) at Screening
10. Must have platelets ≥ 75,000/mL at Screening.
11. Must have International Normalized Ratio (INR) ≤ 1.7 at Screening. Female who is postmenopausal, OR Female who is of childbearing potential (postmenarchal) who agrees to use a highly efficient method of contraception (ie, a method with less than 1% failure rate \[eg, sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner or combined birth control pills\]) from Screening until 90 days after the final dose of MIV-818.
OR Male who agrees to use condoms from Screening until 90 days after the final dose of MIV-818.
OR Male with a female partner of childbearing potential (WOCBP) who is using a highly efficient method of contraception as described above.
13\. WOCBP must have a negative serum pregnancy test at Screening and negative (serum or urine) pregnancy test within 72 h before the first study drug dose.
14\. Must have progressed on or are intolerant of standard therapy with:
1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
2. Histologically or cytologically confirmed iCCA, or
3. Liver metastases from colon, rectal, or gastric solid tumors with limited extrahepatic tumor burden (any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).
Phase 1b Monotherapy-specific Inclusion Criterion:
15\. Must have:
1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
2. Histologically or cytologically confirmed iCCA, or
3. Liver metastases from solid tumors, with limited extrahepatic tumor burden (i.e. no brain or bone metastases), any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).
Combination therapy-specific Inclusion Criterion:
16\. Must have histologically or cytologically confirmed HCC that is considered advanced or unresectable, i.e. not suitable for either surgery, radiofrequency ablation (RFA) or loco-regional therapies (patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and medical monitor). Patients with fibrolamellar HCC or a mixed HCC and iCCA will be excluded.
17\. Must have progressed on or are intolerant of 1or 2 lines of standard therapy for HCC (see also exclusion criterion no. 20) and are now candidates for lenvatinib or pembrolizumab treatment.
2. Able to understand and voluntarily sign a written informed consent and is willing, and able, to comply with the protocol requirements.
3. Must have measurable disease based on RECIST v1.1 as determined by the site study team. Must have at least 1 target lesion in the liver. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
4. Must have a Child-Pugh A status for Phase 1a and a Child-Pugh A or B status for Phase 1b and 2a. SRC discretion to restrict to Child-Pugh A status for Phase 1b and 2a.
5. Must have an ECOG performance status of 0 or 1 at Screening.
6. Must have life expectancy of \> 12 weeks in the investigator's opinion.
7. Must have ALT and AST ≤ 5.0 × upper limit of normal (ULN) at Screening.
8. Must have total bilirubin (TBil) ≤ 3.0 mg/dL at Screening.
9. Must have adequate renal function with estimated creatinine clearance
≥ 60 mL/min (based on Cockcroft and Gault formula or similar) at Screening
10. Must have platelets ≥ 75,000/mL at Screening.
11. Must have International Normalized Ratio (INR) ≤ 1.7 at Screening. Female who is postmenopausal, OR Female who is of childbearing potential (postmenarchal) who agrees to use a highly efficient method of contraception (ie, a method with less than 1% failure rate \[eg, sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner or combined birth control pills\]) from Screening until 90 days after the final dose of MIV-818.
OR Male who agrees to use condoms from Screening until 90 days after the final dose of MIV-818.
OR Male with a female partner of childbearing potential (WOCBP) who is using a highly efficient method of contraception as described above.
13\. WOCBP must have a negative serum pregnancy test at Screening and negative (serum or urine) pregnancy test within 72 h before the first study drug dose.
14\. Must have progressed on or are intolerant of standard therapy with:
1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
2. Histologically or cytologically confirmed iCCA, or
3. Liver metastases from colon, rectal, or gastric solid tumors with limited extrahepatic tumor burden (any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).
Phase 1b Monotherapy-specific Inclusion Criterion:
15\. Must have:
1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or
2. Histologically or cytologically confirmed iCCA, or
3. Liver metastases from solid tumors, with limited extrahepatic tumor burden (i.e. no brain or bone metastases), any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).
Combination therapy-specific Inclusion Criterion:
16\. Must have histologically or cytologically confirmed HCC that is considered advanced or unresectable, i.e. not suitable for either surgery, radiofrequency ablation (RFA) or loco-regional therapies (patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and medical monitor). Patients with fibrolamellar HCC or a mixed HCC and iCCA will be excluded.
17\. Must have progressed on or are intolerant of 1or 2 lines of standard therapy for HCC (see also exclusion criterion no. 20) and are now candidates for lenvatinib or pembrolizumab treatment.
Exclusion Criteria
1. Tumor volume exceeding 50% of liver.
2. History of previous malignancy within the last 5 years except basal cell carcinoma or carcinoma in situ in solid organ.
3. Known CNS or brain metastases, unless previously treated and stable for 3 months.
4. Ongoing significant disease other than target disease as judged by the investigator to compromise the patients' ability to complete this study.
5. History of solid organ transplant or bone marrow transplant.
6. Receiving immunosuppressive therapy including oral corticosteroids.
7. Active hepatitis B (eg, hepatitis B surface antigen \[HBsAg\] reactive) and patients with active hepatitis C (eg, hepatitis C RNA is \[qualitative\] detected).
8. Positive human immunodeficiency virus (HIV) infection.
9. Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.
10. Symptomatic encephalopathy within 3 months prior to Screening and/or requirement for medication for encephalopathy.
11. Esophageal variceal bleeding within 2 weeks prior to Screening.
12. Receiving prior anticancer therapy within 4 weeks prior to first dose of MIV-818.
13. Receiving any other investigational agent within 4 weeks prior to Screening
14. Enrolled in another clinical study with an investigational drug.
15. Presence of residual toxicities of CTCAE Grade \> 1 after prior anticancer therapy within 2 weeks of first treatment with MIV-818, except for alopecia.
16. History of allergic reactions attributed to compounds of similar chemical or biological composition to MIV-818.
17. HCC of diffuse infiltrative type.
18. Receiving drugs that are extensively metabolized by cytochrome P450 (CYP) 3A4 that have a narrow therapeutic index. Drugs that are extensively metabolized by CYP3A4 that have a narrow therapeutic index must be discontinued 5 half-lives before first dose of MIV-818.
Patients are excluded from combination therapy parts of this study if any of the following criteria are met:
19. Patients with a diagnosis of fibrolamellar HCC.
20. Received \>2 lines of therapy for the treatment of advanced HCC.
21. Systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal anti-hypertensive therapy and with no change in anti hypertensive agents within the last 1 week prior to Screening.
22. Women who are breastfeeding.
23. Bleeding disorders or receiving anti-coagulation drugs.
24. Any interventional treatment for esophageal varices required within 28 days of study treatment.
25. Hepatic encephalopathy in the last 6 months.
26. QTc interval is greater than 480 milliseconds at Screening.
27. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
28. Has an active infection requiring systemic therapy.
29. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to planned start of study therapy.
30. Presence of known active tuberculosis (TB; Bacillus tuberculosis).
31. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
32. Known history of, or any evidence of active, non-infectious pneumonitis or has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Exclusion criterion applicable to lenvatinib cohort only:
33. Proteinuria \> 1g / 24 hours. Patients with \> 1+ proteinuria on dipstick testing will need a 24-hour urine protein measured to exclude proteinuria \> 1g / 24 hours.
2. History of previous malignancy within the last 5 years except basal cell carcinoma or carcinoma in situ in solid organ.
3. Known CNS or brain metastases, unless previously treated and stable for 3 months.
4. Ongoing significant disease other than target disease as judged by the investigator to compromise the patients' ability to complete this study.
5. History of solid organ transplant or bone marrow transplant.
6. Receiving immunosuppressive therapy including oral corticosteroids.
7. Active hepatitis B (eg, hepatitis B surface antigen \[HBsAg\] reactive) and patients with active hepatitis C (eg, hepatitis C RNA is \[qualitative\] detected).
8. Positive human immunodeficiency virus (HIV) infection.
9. Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.
10. Symptomatic encephalopathy within 3 months prior to Screening and/or requirement for medication for encephalopathy.
11. Esophageal variceal bleeding within 2 weeks prior to Screening.
12. Receiving prior anticancer therapy within 4 weeks prior to first dose of MIV-818.
13. Receiving any other investigational agent within 4 weeks prior to Screening
14. Enrolled in another clinical study with an investigational drug.
15. Presence of residual toxicities of CTCAE Grade \> 1 after prior anticancer therapy within 2 weeks of first treatment with MIV-818, except for alopecia.
16. History of allergic reactions attributed to compounds of similar chemical or biological composition to MIV-818.
17. HCC of diffuse infiltrative type.
18. Receiving drugs that are extensively metabolized by cytochrome P450 (CYP) 3A4 that have a narrow therapeutic index. Drugs that are extensively metabolized by CYP3A4 that have a narrow therapeutic index must be discontinued 5 half-lives before first dose of MIV-818.
Patients are excluded from combination therapy parts of this study if any of the following criteria are met:
19. Patients with a diagnosis of fibrolamellar HCC.
20. Received \>2 lines of therapy for the treatment of advanced HCC.
21. Systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal anti-hypertensive therapy and with no change in anti hypertensive agents within the last 1 week prior to Screening.
22. Women who are breastfeeding.
23. Bleeding disorders or receiving anti-coagulation drugs.
24. Any interventional treatment for esophageal varices required within 28 days of study treatment.
25. Hepatic encephalopathy in the last 6 months.
26. QTc interval is greater than 480 milliseconds at Screening.
27. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
28. Has an active infection requiring systemic therapy.
29. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to planned start of study therapy.
30. Presence of known active tuberculosis (TB; Bacillus tuberculosis).
31. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
32. Known history of, or any evidence of active, non-infectious pneumonitis or has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Exclusion criterion applicable to lenvatinib cohort only:
33. Proteinuria \> 1g / 24 hours. Patients with \> 1+ proteinuria on dipstick testing will need a 24-hour urine protein measured to exclude proteinuria \> 1g / 24 hours.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medivir
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ruth Plummer, Professor
Role: PRINCIPAL_INVESTIGATOR
Northern Institute for Cancer Research, Newcastle
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antwerp University Hospital
Antwerp, , Belgium
Site Status
University Hospitals Gasthuisberg
Leuven, , Belgium
Site Status
CHA Bundang Medical Center
Gyeonggi-do, , South Korea
Site Status
Pusan National University Hospital
Pusan, , South Korea
Site Status
Asan Medical Center
Seoul, , South Korea
Site Status
Samsung Medical Center
Seoul, , South Korea
Site Status
Seoul National University Hospital
Seoul, , South Korea
Site Status
Severance Hospital
Seoul, , South Korea
Site Status
Hospital Clinic Carrer Rosselló 161
Barcelona, , Spain
Site Status
Hospital Vall Hebrón
Barcelona, , Spain
Site Status
START Barcelona HM Nou Delfos
Barcelona, , Spain
Site Status
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Site Status
Hospital Universitario 12 de Octubre
Madrid, , Spain
Site Status
START Madrid-FJD
Madrid, , Spain
Site Status
Beatson West of Scotland Cancer Care
Glasgow, , United Kingdom
Site Status
Guy's Hospital, Oncology and Clinical Trials
London, , United Kingdom
Site Status
Northern Institute for Cancer Research
Newcastle upon Tyne, , United Kingdom
Site Status
Chruchill Hospital, Cancer and Haematology Centre
Oxford, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Belgium
South Korea
Spain
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIV-818-101/201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
NCT02509507
COMPLETED
PHASE1/PHASE2
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
NCT04170179
UNKNOWN
PHASE2
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
NCT00370513
COMPLETED
PHASE1
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05342194
RECRUITING
PHASE3
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
NCT01774344
COMPLETED
PHASE3
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
NCT03713593
COMPLETED
PHASE3
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
NCT03516071
COMPLETED
PHASE2
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06201065
RECRUITING
PHASE3
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
NCT05797805
RECRUITING
PHASE1/PHASE2
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
NCT03347292
COMPLETED
PHASE1
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
NCT03006926
COMPLETED
PHASE1
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
NCT01658878
COMPLETED
PHASE1/PHASE2
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
NCT05509478
UNKNOWN
PHASE2
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
NCT05010681
RECRUITING
PHASE2
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
NCT04194775
ACTIVE_NOT_RECRUITING
PHASE3
Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
NCT04656249
COMPLETED
PHASE2
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
NCT04044313
COMPLETED
PHASE2
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
NCT00437424
COMPLETED
PHASE1
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
NCT00872014
COMPLETED
PHASE2
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
NCT02828124
TERMINATED
PHASE1/PHASE2
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
NCT04361331
COMPLETED
PHASE2
Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment
NCT03644511
TERMINATED
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
NCT06858813
RECRUITING
PHASE1
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
NCT04170556
COMPLETED
PHASE1/PHASE2